Open AccessTriple targeted therapy is a new perspective treatment strategy for patients with FLT3-mutated acute myeloid leukemia. the literature review and single-centre experience
Author(s) -
A. E. Prokopyev,
Aleksina Shatilova,
Irina Budaeva,
А. И. Решетова,
Renat Badaev,
Dmitriy Motorin,
K. A. Kovalchuk,
Alina E Ershova,
Elena Tochenaya,
В. В. Иванов,
Константин Богданов,
Yu. V. Mirolyubova,
E. V. Tolstopyatova,
Tatiaikulina,
Yu. A. Alekseeva,
Larisa Girshova
Publication year - 2022
Publication title -
rossijskij žurnal personalizirovannoj mediciny
Language(s) - English
Resource type - Journals
eISSN - 2782-3814
pISSN - 2782-3806
DOI - 10.18705/2782-3806-2022-2-4-63-86
Subject(s) - medicine , fms like tyrosine kinase 3 , myeloid leukemia , oncology , venetoclax , refractory (planetary science) , regimen , azacitidine , combination therapy , tyrosine kinase inhibitor , targeted therapy , leukemia , mutation , cancer , chronic lymphocytic leukemia , biochemistry , gene expression , astrobiology , dna methylation , gene , chemistry , physics